It is tempting to speculate that specific HLA genotypes may negatively impact early immune surveillance in pediatric cancers, whereas HLA class I and APP antigen loss, mostly through transcriptional silencing, further contribute to tumor progression, relapse and/or dissemination. The gene discussed is APP; the disease is neoplasm.